Nat Biotechnol · 2016
Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9
Doench JG, Fusi N, Sullender M, Hegde M, Vaimberg EW, Donovan KF, Smith I, Tothova Z, Wilen C, Orchard R, Virgin HW, Listgarten J, Root DE.
Show affiliations
- Doench JG — Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
- Fusi N — Microsoft Research New England, Cambridge, Massachusetts, USA.
- Sullender M — Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
- Hegde M — Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
- Vaimberg EW — Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
- Donovan KF — Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
- Smith I — Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
- Tothova Z — Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
- Wilen C — Washington University School of Medicine, Department of Pathology and Immunology, St. Louis, Missouri, USA.
- Orchard R — Washington University School of Medicine, Department of Pathology and Immunology, St. Louis, Missouri, USA.
- Virgin HW — Washington University School of Medicine, Department of Pathology and Immunology, St. Louis, Missouri, USA.
- Listgarten J — Microsoft Research New England, Cambridge, Massachusetts, USA.
- Root DE — Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
78 read11 want to readRigor 2.9Novelty 3.0Impact 3.1Reprod. 2.8
Most-cited papers citing this
- Elife · 2026 · cited by 9
- Chem Soc Rev · 2026 · cited by 4
- Science · 2026 · cited by 3
- Nature · 2026 · cited by 2
- Nat Commun · 2026 · cited by 2
Log in to like, log, and share thoughts on this paper.
Discussion
Share your thoughts above to start a thread. Constructive feedback only — reply to and like others’ posts.
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0